Editor's Choice
PUBLIC HEALTH / CLINICAL RESEARCH
 
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The aim of the study was to create a valuable practical tool for evaluating the risk of developing long COVID.

Material and methods:
1150 patients from the Polish STOP-COVID registry (PoLoCOV study) were used to develop the risk score. The patients were ill between 03/2020 and 04/2022. To develop a clinically useful scoring model, the LC risk score was generated using the machine learning-based framework AutoScore. Patient data were first randomised into a training (70% of output) and a test (30% of output) cohort. Due to the relatively small study group, cross-validation was used. Model predictive ability was evaluated based on the ROC curve and the AUC value. The result of the risk score for a given patient was the total value of points assigned to selected variables.

Results:
To create the LC risk score, eight variables were ultimately selected due to their significance and clinical value. Female gender significantly contributed to higher final outcome values, with age range 40–49, body mass index < 18.5 kg/m2, hospitalisation during active disease, arthralgia, myalgia as well as loss of taste and smell during infection, COVID-19 symptoms lasting at least 14 days, and unvaccinated status. The final predictive value of the developed LC risk score for a cut-off of 58 points was AUC = 0.630 (95% CI: 0.571–0.688) with sensitivity 39.80%, specificity 85.1%, positive predictive value 80.8%, and negative predictive value 47.3%.

Conclusions:
The LC risk score may be a practical and undemanding utility that employs basic sociodemographic data, vaccination status, and symptoms during COVID-19 to assess the risk of long COVID.

 
REFERENCES (39)
1.
COVID - Coronavirus Statistics - Worldometer 2023.
 
2.
WHO A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus, 6 October 2021; 2021;.
 
3.
NICE. National Institute for Health and Care Excellence Overview. COVID-19 Rapid Guideline: Managing the Long-Term Effects of COVID-19. Guidance. NICE 2021; 1-111.
 
4.
Pazukhina E, Andreeva M, Spiridonova E, et al. Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge: a prospective, cohort study in Moscow (StopCOVID). BMC Med 2022; 20: 244.
 
5.
O’Mahoney LL, Routen A, Gillies C, et al. The prevalence and long-term health effects of long covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. eClinicalMedicine 2023; 55: 101762.
 
6.
Chudzik M, Babicki M, Kapusta J, et al. Long-COVID clinical features and risk factors: a retrospective analysis of patients from the STOP-COVID Registry of the PoLoCOV Study. Viruses 2022; 14: 1755.
 
7.
Tsampasian V, Elghazaly H, Chattopadhyay R, et al. Risk Factors associated with post-COVID-19 condition a systematic review and meta-analysis. JAMA Intern Med 2023; 183: 566-80.
 
8.
Lewek J, Jatczak-Pawlik I, Maciejewski M, Jankowski P, Banach M. COVID-19 and cardiovascular complications – preliminary results of the LATE-COVID Study. Arch Med Sci 2021; 17: 818-22.
 
9.
Jatczak-Pawlik I, Lewek J, Czkwianianc E, et al. Biochemical and cardiovascular predictors of PIMS-TS risk in children after COVID-19 recovery: preliminary results of the LATE-COVID-Kids Study. Arch Med Sci 2022; 18: 545-52.
 
10.
Babicki M, Kapusta J, Pieniawska-Śmiech K, et al. Do COVID-19 vaccinations affect the most common post-COVID symptoms? Initial data from the STOP-COVID register-12-month follow-up. Viruses 2023; 15: 1370.
 
11.
Batiha GES, Al-kuraishy HM, Al-Gareeb AI, Welson NN. Pathophysiology of post-COVID syndromes: a new perspective. Virol J 2022; 19: 158.
 
12.
Nittas V, Gao M, West EA, et al. Long COVID through a public health lens: an umbrella review. Public Health Rev 2022; 43: 1604501.
 
13.
Cutler DM. The costs of long COVID. JAMA Heal Forum 2022; 3: e221809.
 
14.
Saffari SE, Ning Y, Xie F, et al. AutoScore-Ordinal: an interpretable machine learning framework for generating scoring models for ordinal outcomes. BMC Med Res Methodol 2022; 22: 286.
 
15.
Xie F, Ong MEH, Liew JNMH, et al. Development and assessment of an interpretable machine learning triage tool for estimating mortality after emergency admissions. JAMA Netw Open 2021; 4: e2118467.
 
16.
Liu N, Liu M, Chen X, et al. Development and validation of an interpretable prehospital return of spontaneous circulation (P-ROSC) score for patients with out-of-hospital cardiac arrest using machine learning: a retrospective study. eClinicalMedicine 2022; 48: 101422.
 
17.
Ang Y, Li S, Ong MEH, et al. Development and validation of an interpretable clinical score for early identification of acute kidney injury at the emergency department. Sci. Rep 2022; 12: 7111.
 
18.
Zierle-Ghosh A, Jan A. Physiology, Body Mass Index (BMI); StatPearls Publishing, 2018.
 
19.
Xie F, Ning Y, Liu M, et al. A universal autoscore framework to develop interpretable scoring systems for predicting common types of clinical outcomes. STAR Protoc 2023; 4: 102302.
 
20.
Xie F, Chakraborty B, Hock Ong ME, Goldstein BA, Liu N. AutoScore: a machine learning–based automatic clinical score generator and its application to mortality prediction using electronic health records. JMIR Med Inform 2020; 8: 21798.
 
21.
RStudio Team (2020). RStudio: Integrated Development for R. RStudio. Available Online Available online: https://posit.co/ (accessed on 12 October 2023).
 
22.
Cervia C, Zurbuchen Y, Taeschler P, et al. Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome. Nat Commun 2022; 13: 446.
 
23.
Gopichandran V, Sakthivel K. Doctor-patient communication and trust in doctors during COVID 19 times – a cross sectional study in Chennai, India. PLoS One 2021; 16: e0253497.
 
24.
Nowowiejska-Wiewióra A, Wita K, Mędrala Z, et al. Dyslipidemia treatment and attainment of LDL-cholesterol treatment goals in patients participating in the managed care for acute myocardial infarction survivors program. Kardiol Pol 2023; 81: 359-65.
 
25.
Tsampasian V, Elghazaly H, Chattopadhyay R, et al. Risk factors associated with post-COVID-19 condition: a systematic review and meta-analysis. JAMA Intern Med 2023; 183: 566-80.
 
26.
Leontsinis I, Papademetriou V, Chrysohoou C, et al. Hypertensive urgencies during the first wave of the COVID-19 pandemic in a tertiary hospital setting: a u-shaped alarming curve. Arch Med Sci 2021; 18: 982-90.
 
27.
Bai F, Tomasoni D, Falcinella C, et al. Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect 2022; 28: 611.e9.
 
28.
Ye P, Pang R, Li L, et al. Both Underweight and obesity are associated with an increased risk of coronavirus disease 2019 (COVID-19) severity. Front Nutr 2021; 8: 649422.
 
29.
Notarte KI, Catahay JA, Velasco JV, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. eClinicalMedicine 2022; 53: 101624.
 
30.
Byambasuren O, Stehlik P, Clark J, Alcorn K, Glasziou P. Effect of covid-19 vaccination on long covid: systematic review. BMJ Med 2023; 2: e000385.
 
31.
Sapkota HR, Nune A. Long COVID from rheumatology perspective – a narrative review. Clin Rheumatol 2022; 41: 337.
 
32.
Petersen MS, Kristiansen MF, Hanusson KD, et al. Long COVID in the Faroe Islands: a longitudinal study among nonhospitalized patients. Clin Infect Dis 2021; 73: e4058-4063.
 
33.
Li J, Zhou Y, Ma J, et al. The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID. Signal Transduct Target Ther 2023; 8: 416.
 
34.
Rutkai I, Mayer MG, Hellmers LM, et al. Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates. Nat Commun 2022; 13: 1745.
 
35.
Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med 2021; 27: 626-31.
 
36.
Perlis RH, Santillana M, Ognyanova K, et al. Prevalence and correlates of long COVID symptoms among US adults. JAMA Netw Open 2022; 5: E2238804.
 
37.
Subramanian A, Nirantharakumar K, Hughes S, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat Med 2022; 28: 1706-14.
 
38.
Mateu L, Tebe C, Loste C, et al. Determinants of the onset and prognosis of the post-COVID-19 condition: a 2-year prospective observational cohort study. Lancet Reg Health Eur 2023; 33: 100724.
 
39.
Xie Y, Choi T, Al-Aly Z. Association of treatment with nirmatrelvir and the risk of post-COVID-19 condition. JAMA Intern Med 2023; 183: 554-64.
 
eISSN:1896-9151
ISSN:1734-1922
Journals System - logo
Scroll to top